Some new drugs recently approved and in clinical development with possible activity against resistant viruses
| Drug class | Stage of development | Comments |
|---|---|---|
| NRTIs: | ||
| Tenofovir | Approved | Active against TAMs11 |
| Amdoxovir (DAPD) | Phase I/II | Active against various NRTI associated mutations, but not necessarily multidrug resistance7,8 |
| Alovudine | Phase I/II | Activity against TAMs and antagonism with AZT and d4T4,5 |
| nNRTIs: | ||
| TMC120 | Phase I/II | Second generation nNRTIs active against nNRTI resistant viruses13,14 |
| TMC125 | Phase I/II | |
| Capravirine | Phase I/II | Activity against K103N/V106/L100I mutants. Mutations at 181 codon confer high level resistance15 |
| PIs | ||
| Atazanavir | Phase III | Favourable resistance profile in PI naive, but unclear cross resistance pattern in PI experienced. Good side effects profiles16 |
| Tipranavir | Phase I/II | Likely to be effective in patients with experience of multiple protease inhibitors19 |
| Fusion inhibitors | ||
| Enfuvirtide (T-20) | Phase III | Active against multidrug resistant viruses20,21 |